SENATE DOCKET, NO. 578        FILED ON: 2/2/2021

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1393

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Brendan P. Crighton

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to expand access to Naloxone.

_______________

PETITION OF:

SENATE DOCKET, NO. 578        FILED ON: 2/2/2021

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1393

The Commonwealth of Massachusetts

_______________

In the One Hundred and Ninety-Second General Court
(2021-2022)

_______________

An Act to expand access to Naloxone.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Chapter 94C of the General Laws is hereby amended by inserting after section 18C the following new section:-

Section 18D. In the event that a practitioner issues a prescription for an opioid contained in Schedule II of section 3, the practitioner shall also issue a prescription for an opioid antagonist if one of the following conditions is present: (i) the patient is prescribed an opioid which individually or in aggregate with other medications is more than equal to 50 morphine milligram equivalents per day; (ii) the patient is prescribed any dose of an opioid when a benzodiazepine has been prescribed in the past 30 days or will be prescribed at the visit; or (iii) the patient has a prior history of opioid use disorder or overdose or has a history of substance use disorder. If the practitioner does not co-prescribe an opioid antagonist at the time said prescription for an opioid is issued, the practitioner shall document in the patient’s medical record why co-prescription of an opioid antagonist was not appropriate for the patient.